Next generation therapies change the landscape in melanoma

بواسطة Flaherty, Keith T.
منشور في 2011

When are signal transduction targeted therapies acting as immunotherapy?

بواسطة Flaherty, Keith T
الحاوية / القاعدة Cancer Biol Ther (2015)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

بواسطة Sullivan, Ryan J., Flaherty, Keith T.
منشور في 2011

Moving treatments earlier to move further forward

بواسطة Davies, Michael A., Flaherty, Keith T.
الحاوية / القاعدة Nat Rev Clin Oncol (2017)

Targeting the RAS pathway in melanoma

بواسطة Ji, Zhenyu, Flaherty, Keith T., Tsao, Hensin
منشور في 2011

Biological challenges of BRAF inhibitor therapy

بواسطة Puzanov, Igor, Burnett, Patrick, Flaherty, Keith T.
الحاوية / القاعدة Mol Oncol (2011)

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

بواسطة Bai, Xue, Fisher, David E., Flaherty, Keith T.
الحاوية / القاعدة Nat Rev Clin Oncol (2019)

Mutation-driven drug development in melanoma

بواسطة Flaherty, Keith T., Hodi, F. Stephen, Bastian, Boris C.
منشور في 2010

Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

بواسطة Wargo, Jennifer A., Cooper, Zachary A., Flaherty, Keith T.
الحاوية / القاعدة Cancer Discov (2014)

Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma

بواسطة Verduzco, Daniel, Flaherty, Keith T., Smalley, Keiran S.M.
الحاوية / القاعدة Exp Dermatol (2015)

YAP in MAPK pathway targeted therapy resistance

بواسطة Flaherty, Keith T, Wargo, Jennifer A, Bivona, Trever G
الحاوية / القاعدة Cell Cycle (2015)

Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy

بواسطة Lo, Jennifer A., Fisher, David E., Flaherty, Keith T.
الحاوية / القاعدة JAMA Oncol (2015)

Mechanisms of resistance to immune checkpoint inhibitors

بواسطة Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
الحاوية / القاعدة Br J Cancer (2018)

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be

بواسطة Sullivan, Ryan J., LoRusso, Patricia M., Flaherty, Keith T.
منشور في 2013

The Conundrum of Genetic “Drivers” in Benign Conditions

بواسطة Kato, Shumei, Lippman, Scott M., Flaherty, Keith T., Kurzrock, Razelle
الحاوية / القاعدة J Natl Cancer Inst (2016)

Melanoma: New Insights and New Therapies

بواسطة Nikolaou, Vasiliki A., Stratigos, Alexander J., Flaherty, Keith T., Tsao, Hensin
منشور في 2012

Precision medicine for cancer with next-generation functional diagnostics

بواسطة Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T.
الحاوية / القاعدة Nat Rev Cancer (2015)

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

بواسطة Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
الحاوية / القاعدة Oncotarget (2015)

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

بواسطة Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
الحاوية / القاعدة J Invest Dermatol (2015)

A Melanoma Molecular Disease Model

بواسطة Vidwans, Smruti J., Flaherty, Keith T., Fisher, David E., Tenenbaum, Jay M., Travers, Michael D., Shrager, Jeff
منشور في 2011